Our study confirms the efficacy and safety of anti-PD-1 inhibition in patients with advanced cSCC reported in phase I and II clinical trials [25,27,28,29,30,31,32] in a real-world setting. Here, PDCD1 is linked to skin squamous cell carcinoma.